31results about How to "Improve disposal" patented technology

A combustor apparatus is provided, comprising a mixing arrangement for mixing a carbonaceous fuel with enriched oxygen and a working fluid to form a fuel mixture. A combustion chamber is at least partially defined by a porous perimetric transpiration member, at least partially surrounded by a pressure containment member. The combustion chamber has longitudinally spaced apart inlet and outlet portions. The fuel mixture is received by the inlet portion for combustion within the combustion chamber at a combustion temperature to form a combustion product. The combustion chamber directs the combustion product longitudinally toward the outlet portion. The transpiration member is configured to substantially uniformly direct a transpiration substance therethrough toward the combustion chamber, such that the transpiration substance is directed to flow helically about the perimeter and longitudinally between the inlet and outlet portions, for buffering interaction between the combustion product and the transpiration member. Associated systems are also provided.

A combustor apparatus is provided, comprising a mixing arrangement for mixing a carbonaceous fuel with enriched oxygen and a working fluid to form a fuel mixture. A combustion chamber is at least partially defined by a porous perimetric transpiration member, at least partially surrounded by a pressure containment member. The combustion chamber has longitudinally spaced apart inlet and outlet portions. The fuel mixture is received by the inlet portion for combustion within the combustion chamber at a combustion temperature to form a combustion product. The combustion chamber directs the combustion product longitudinally toward the outlet portion. The transpiration member is configured to substantially uniformly direct a transpiration substance therethrough toward the combustion chamber, such that the transpiration substance is directed to flow helically about the perimeter and longitudinally between the inlet and outlet portions, for buffering interaction between the combustion product and the transpiration member. Associated systems are also provided.

A combustor apparatus is provided, comprising a mixing arrangement for mixing a carbonaceous fuel with enriched oxygen and a working fluid to form a fuel mixture. A combustion chamber is at least partially defined by a porous perimetric transpiration member, at least partially surrounded by a pressure containment member. The combustion chamber has longitudinally spaced apart inlet and outlet portions. The fuel mixture is received by the inlet portion for combustion within the combustion chamber at a combustion temperature to form a combustion product. The combustion chamber further directs the combustion product longitudinally toward the outlet portion. The porous transpiration member is configured to substantially uniformly direct a transpiration substance laterally therethrough, about the perimeter thereof defining the combustion chamber and longitudinally between the inlet and outlet portions, toward the combustion chamber for buffering interaction between the combustion product and the porous transpiration member. Associated systems are also provided.

The present invention provides peptide analogues which are antagonists of gastric inhibitory peptide (GIP). The peptides, based on GIP 1-42 include substitutions and / or modifications which have enhanced resistance to degradation by the enzyme dipeptidyl peptidase IV (DPP IV). The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes.

A hydroxy camptothecin lipid used for preparing freeze-dried powder injection is prepared from hydroxy camptothecin, phosphatide or cholesterine through dissolving them in organic solvent, spinning evaporating at 40-70 deg.C to become film, adding the buffering liquid containing surfactant, cold storing for hydrating, and stirring.

The present invention provides peptide analogues which are antagonists of gastric inhibitory peptide (GIP). The peptides, based on GIP 1-42 include substitutions and / or modifications which have enhanced resistance to degradation by the enzyme dipeptidyl peptidase IV (DPP IV). The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes.

A semiconductor device comprises: a semiconductor chip; an extension portion formed in contact with the side surfaces so as to surround the semiconductor chip; an insulating film formed on a surface of the extension portion and the semiconductor chip; each of a plurality of wiring patterns electrically connected to each electrode pad, respectively and extended from the electrode pads to the surface of the extension portion; a sealing portion formed such that a part of each of the wiring patterns is exposed; and a plurality of external terminals provided over the wiring patterns in a region including the upper side of the extension portion.

A hydroxy camptothecin lipid used for preparing freeze-dried powder injection is prepared from hydroxy camptothecin, phosphatide or cholesterine through dissolving them in organic solvent, spinning evaporating at 40-70 deg.C to become film, adding the buffering liquid containing surfactant, cold storing for hydrating, and stirring.

The invention aims to provide a method for preparing a docetaxel long-circulating liposome. The method comprises the following steps of: dissolving docetaxel and carrier materials such as phospholipid, cholesterol and the like together in an organic solvent; forming a film through rotary evaporation in a 40 to 70 DEG C water bath; adding buffer solution which contains a surfactant and performing refrigeration at the temperature of below 4 DEG C for 10 to 60 minutes to fully hydrate the film; and then mixing or stirring to obtain the docetaxel liposome. The liposome of 70 to 500nm is prepared from the docetaxel and can be prepared into docetaxel long-circulating liposome frozen powder for injection by lyophilization.

In an electric driving apparatus, a sensor magnet is fixed to a first end portion of a rotary shaft of a motor. A sensor device includes a rotation sensor that detects a magnetic field generated by the sensor magnet. The rotation sensor opposes the sensor magnet in an axial direction of the rotary shaft. A control unit mounted on the motor includes an inverter circuit that is connected to an armature winding of the motor via a plurality of feeder wires. The inverter circuit is disposed in a position further from the sensor magnet than the rotation sensor in the axial direction of the rotary shaft. A shield plate formed from a magnetic material is disposed between the rotation sensor and the inverter circuit.

The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.

The subject invention provides materials and methods for reducing deleterious atmospheric gases, such as greenhouse gases. In specific embodiments, the reduction in deleterious atmospheric gases is achieved via enhanced vegetative carbon utilization and storage, as well as increased carbon sequestration in soil. In some embodiments, the subject invention can be used for reducing the number of carbon credits used by an operator involved in, e.g., agriculture, livestock production, waste management or other industries. In certain embodiments, the subject invention provides customizable microbe-based products, as well as methods of using these microbe-based products for reduction of greenhouse gases and / or enhanced sequestration of carbon.

In the operation of smoking / burning type volume reduction treatment apparatus (1), referring to view (A), charcoal carbonized layer (T2) is spread over powdery ceramic layer (T1) in the state of having negative ion air fed through air supply inlet (H). Further, sawdust layer (T3) is spread thereover, and thereafter treatment subject layer (V) is piled thereon. In a temporary burning region of the carbonized layer (T2), the powdery ceramic layer (T1) exerts not only heat storing action but also heat radiation action. Referring to view (B), the interior of the sawdust layer (T3) is altered into temporary carbonized layer (T3 1) and temporary dried layer (T3 2). As the temporary burning region slowly moves upward, an under side of the treatment subject layer (V) is altered into dried layer (V1) and further, carbonized layer (V2) shown in view (C) is formed. Thereafter, this carbonized layer (V2) catches fire, so that burning region (V3) is formed in layered form in the treatment subject layer (V). Thus, smoking / burning starts. Accordingly, there can be provided a method wherein a burning region is securely formed in the treatment subject within the apparatus (1).

A semiconductor device comprises: a base; a semiconductor chip provided on the base which includes a first main surface 20a on which a plurality of electrode pads is provided, a surface protecting film provided on the first main surface, a second main surface which opposes the first main surface, and a plurality of side surfaces between the surface of the surface protecting film and the second main surface; an insulating extension portion formed so as to surround the side surfaces of the semiconductor chip; a plurality of wiring patterns electrically connected to the electrode pads, respectively and extended from the electrode pads to the surface of the extension portion; a sealing portion formed on the wiring patterns such that a part of each of the wiring patterns is exposed; and a plurality of external terminals provided on the wiring patterns in a region including the upper side of the extension portion.

The present invention relates to methods and compositions for treating type II diabetes. This invention discloses an orally administrable pharmaceutical formulation, as convenient therapy to reduce glucose levels in blood, preventing the development of diabetes and an earlier exhausting of the pancreas. In certain embodiments, the invention provides orally administerable combination pharmaceutical formulations, comprising at least one insulin sensitizer (e.g., a glitazone such as pioglitazone or rosiglitazone), at least one sulfonylurea (e.g., glimepiride), and at least one biguanide (e.g., metformin or a pharmaceutically acceptable salt or ester thereof, such as metformin HCl). The present invention also provides methods of treating type II diabetes and related disorders in a mammal, suitably a human, by administering to a mammal in need thereof one or more of the compositions of the present invention.

The invention discloses a hydroxyl camptothecin flexible liposome and a preparation method thereof. The method comprises the following steps of: dissolving hydroxyl camptothecin and carrier materials, such as phospholipid, cholesterol and the like, in an organic solvent; forming the mixture into a membrane in water bath through rotary evaporation; and adding buffer solution which contains chitosan into the membrane to form the hydroxyl camptothecin flexible liposome. The hydroxyl camptothecin flexible liposome is relatively lower in toxicity, relatively longer in residence time in a body, high in stability in a solution phase and smalllow in particle size, and the particle size of the liposome is not obviously changed after the liposome is lyophilized.

New gene therapy constructions and compositions are the subject of present invention. The gene therapy compositions consist in adeno-associated vectors which jointly express insulin (Ins) and glucokinase (Gck) genes. The new gene therapy constructions are useful for treatment of diabetes either in dogs or human beings.

The present invention provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion proteins are GLP1 receptor agonists that comprise a modified GLP1 fused to a stabilizing domain. In some embodiments, the fusion proteins comprising modified GLP1 are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.

The invention concerns a peptide based on biologically active CCK-8. The peptide has improved characteristics for the treatment of at least one of obesity and type 2 diabetes and has the structure:(Z)-Asp1-Aaa2(X)-Aaa3Gly4Trp5Aaa6Asp7(Y)Aaa8K,wherein the amino acids may be either D or L amino acids; the bond between amino acid residues is either a peptide bond or a non-peptide isostere bond; Aaa2 is selected from the group comprising Tyr and Phe; when Aaa2 is Tyr, X is selected from the group comprising SO3H−, PO3H2− and a polymer moiety of the general formula —O—(CH2—O—CH2)n—H, in which n is an integer between 1 and about 22, wherein the X is covalently bound to the para phenyl oxygen of Tyr, and, when Aaa2 is Phe, X is CH2SO3Na, wherein the X is covalently bound to the para phenyl position of Phe; Aaa3 is selected from the group comprising Met, norleucine, 2-aminohexanoic acid and Thr; Aaa6 is selected from the group comprising Met, norleucine, 2-aminohexanoic acid and Phe; Aaa8 is selected from the group comprising Phe and Met; Y is covalently bound to the nitrogen of Aaa8 and is selected from the group consisting of H and CH3; K is selected from the group consisting of the hydroxyl group of Phe8, an amide covalently bound to Phe8, an ester covalently bound to Phe8, a salt of the hydroxyl group of Phe8, a salt of an amide covalently bound to Phe8, a salt of an ester covalently bound to Phe8 and a polymer moiety of the general formula —O—(CH2—O—CH2)n—H, in which n is an integer between 1 and about 22; and Z comprises at least one amino acid modification, wherein said at least one modification comprises an N-terminal extension, or an N-terminal modification, but excludes Asp1-glucitol CCK-8 where Aaa2 is Tyr and X is SO3H−.The peptides, and Asp1-glucitol CCK-8, are useful to at least one of inhibit food intake, induce satiety, stimulate insulin secretion, moderate blood glucose excursions, enhance glucose disposal and exhibit enhanced stability in plasma compared to native CCK-8

The invention discloses a hydroxyl camptothecin flexible liposome and a preparation method thereof. The method comprises the following steps of: dissolving hydroxyl camptothecin and carrier materials, such as phospholipid, cholesterol and the like, in an organic solvent; forming the mixture into a membrane in water bath through rotary evaporation; and adding buffer solution which contains chitosan into the membrane to form the hydroxyl camptothecin flexible liposome. The hydroxyl camptothecin flexible liposome is relatively lower in toxicity, relatively longer in residence time in a body, high in stability in a solution phase and smalllow in particle size, and the particle size of the liposome is not obviously changed after the liposome is lyophilized.

In an electric driving apparatus, a sensor magnet is fixed to a first end portion of a rotary shaft of a motor. A sensor device includes a rotation sensor that detects a magnetic field generated by the sensor magnet. The rotation sensor opposes the sensor magnet in an axial direction of the rotary shaft. A control unit mounted on the motor includes an inverter circuit that is connected to an armature winding of the motor via a plurality of feeder wires. The inverter circuit is disposed in a position further from the sensor magnet than the rotation sensor in the axial direction of the rotary shaft. A shield plate formed from a magnetic material is disposed between the rotation sensor and the inverter circuit.

A semiconductor device comprises: a base; a semiconductor chip provided on the base which includes a first main surface 20a on which a plurality of electrode pads is provided, a surface protecting film provided on the first main surface, a second main surface which opposes the first main surface, and a plurality of side surfaces between the surface of the surface protecting film and the second main surface; an insulating extension portion formed so as to surround the side surfaces of the semiconductor chip; a plurality of wiring patterns electrically connected to the electrode pads, respectively and extended from the electrode pads to the surface of the extension portion; a sealing portion formed on the wiring patterns such that a part of each of the wiring patterns is exposed; and a plurality of external terminals provided on the wiring patterns in a region including the upper side of the extension portion.

The present invention relates to novel compounds that are useful in the treatment of metabolic disorders, particularly Type II diabetes mellitus and related disorders, and also to the methods for the making and use of such compounds.

The present invention provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion proteins are GLP1 receptor agonists that comprise a modified GLP1 fused to a stabilizing domain. In some embodiments, the fusion proteins comprising modified GLP1 are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.

Pharmaceutical compositions containing an FBPase inhibitor and an insulin sensitizer are provided as well as methods for treating diabetes and diseases responding to increased glycemic control, an improvement in insulin sensitivity, a reduction in insulin levels, or an enhancement of insulin secretion.